Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group.
The designation "clinically localized prostate cancer" comprises a group of biologically heterogeneous tumours with different growth rates and risks of relapse. Because prostate cancer is primarily a disease of older men, treatment selection must take into account the prognosis of the tumour, patient age, comorbidities, side effects of treatment, and patient preferences. Clinical trials must identify the various prognostic groups and test the appropriate treatment strategies within these subgroups.
Parulekar
W R
WR
National Cancer Institute of Canada Clinical Trials Group, Kingston, ON. wparulekar@ctg.queensu.ca
McKenzie
M
M
Chi
K N
KN
Klotz
L
L
Catton
C
C
Brundage
M
M
Ding
K
K
Hiltz
A
A
Meyer
R
R
Saad
F
F